Phase 1 Dose Escalation Study of RXIM002 in Autoimmune Cytopenias

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
The Phase 1 is to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of RXIM002 in patients with relapsed or refractory autoimmune cytopenias.
Epistemonikos ID: 037c93531fba5c349b8f38979030b9e31c4c02a8
First added on: Aug 14, 2026